Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058023 | 0.97 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL8027073 | 0.83 | MTNR1A (0.63) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL5022626 | 0.83 | POLB (0.58) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL13783466 | 0.80 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL992202 | 0.80 | RAB9A (0.73) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL9428464 | 0.79 | MTNR1A (0.65) | NPC1RAB9AKMT2AKDM4EPOLB | |
| SCHEMBL11782014 | 0.79 | POLB (0.55) | NPC1RAB9AMEN1KMT2APLAU | |
| SCHEMBL9939050 | 0.78 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2ACASP3 | |
| Methane SCHEMBL2365682 | 0.78 | RAB9A (0.70) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL1672113 | 0.78 | RAB9A (0.72) | NPC1RAB9AMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-04-21 | — | — | US | disclosed |
| US-9249132-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2651871-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 Pharmaceuticls, Inc. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012083171-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20090182001-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
| EP-1910365-A4 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1910365-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015837-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182001-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, BUB1B | NPC1 3878/4885RAB9A 2746/4885MEN1 969/4885 |
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NPC1 1497/4885RAB9A 3436/4885MEN1 4669/4885 |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NPC1 1497/4885RAB9A 3436/4885MEN1 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.